Medtronic's weaker-than-expected outlook clouds quarterly results beat
Adds CFO comments in paragraphs 5 and 10, graphic
By Pratik Jain and Christy Santhosh
May 23 (Reuters) -Medtronic MDT.N beat estimates for fourth-quarter revenue and profit on Thursday, helped by robust sales of its medical devices, but shares declined more than 3% after its forecast for the current quarter fell short of Wall Street expectations.
Investor anticipation around the sales of medical devices has grown lately, as people, especially older adults, returned to hospitals for medical procedures deferred during the COVID-19 pandemic.
Medtronic's fiscal 2025 adjusted per-share profit forecast of $5.40 to $5.50 came in line with analysts' expectations, but its first-quarter outlook of $1.19 to $1.21 was below LSEG estimates of $1.25.
The company, for which China comprises roughly 7% of the total revenue, said it expects the recently announced U.S. tariff increases on an array of Chinese imports, including medical products, to be short term.
"The Chinese government heavily relies on imported medical devices to serve the patient population," CFO Karen Parkhill told Reuters.
Medtronic has also been facing pricing pressure due to an impact from the Chinese government's volume-based procurement (VBP), under which the country buys medical devices in bulk at a sharp discount.
But Parkhill said the impact of VBP in China is largely behind the company.
Medtronic posted adjusted profit of $1.46 per share for the fourth quarter, compared with analysts' estimate of $1.45 per share.
It, however, expects profit in the first quarter will be hurt 6% due to a stronger dollar.
"The impact from currency lessens through the year, so we expect to be ending the year with high single-digit EPS growth ... in line with our longer-term objective," Parkhill said.
The Dublin-based company reported total revenue of $8.59 billion in the quarter ended April 26, above analysts' estimate of $8.44 billion.
Sales at the company's neuroscience unit, its second largest, rose 5.6% in the quarter, while the diabetes unit posted a 10.9% increase.
However, sales in the company's heart devices unit — its biggest revenue driver — fell 5.2% to $3.13 billion, narrowly missing estimates of $3.14 billion, on soft demand for certain devices used for repair and replacement of heart valves.
Medtronic's Q4 revenue by segments https://reut.rs/4bRbCxy
Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
